Olema Q2 2026 net loss widens to $63.2 million from $43.8 million
Olema Pharmaceuticals reported a second-quarter 2026 net loss of $63.2 million, up from $43.8 million a year earlier, as spending rose on late-stage clinical trials and corporate costs. The statement of operations shows no revenue line, and the company ended the quarter with $461.1 million in cash, cash equivalents, and marketable securities. The company now expects top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027.
Key points
- Net loss was $63.2 million, or $0.61 per share, versus $43.8 million, or $0.51 per share, in the second quarter of 2025.
- GAAP R&D expenses rose to $57.8 million from $43.9 million; G&A expenses rose to $9.4 million from $4.0 million.
- Cash, cash equivalents, and marketable securities were $461.1 million as of June 30, 2026.
- Enrollment in the pivotal Phase 3 OPERA-01 trial is complete; top-line data are expected in Q1 2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.